A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis Pardanani, A. D., Gotlib, J., Jamieson, C., Cortes, J., Talpaz, M., Stone, R. M., Silverman, M. H., Shorr, J., Gilliland, D., Tefferi, A. AMER SOC HEMATOLOGY. 2008: 43–44

View details for Web of Science ID 000262104700098